In a move to avert substantial tariffs, Sanofi has reached an agreement with the U.S. government promising increased access to affordable medications for American patients [[1]]. The deal, announced December 19, comes as the administration continues to pressure pharmaceutical companies to lower drug prices or face a 100% tax on imported patented drugs [[3]]. this agreement with Sanofi, along with similar arrangements reached with AstraZeneca, Novo Nordisk and Merck, signals a broader trend of negotiated solutions amid ongoing debate over pharmaceutical pricing and domestic manufacturing [[2]].
Sanofi has reached an agreement with the U.S. government to avoid potential tariffs on its products, the French pharmaceutical giant announced on December 19. The deal, which is confidential in its specifics, will provide Americans with “better access to more affordable medicines” in exchange for tariff exemptions, according to a company statement.
The agreement establishes “a framework for American patients to benefit from lower prices and exempts Sanofi from duties,” the company said. It also fulfills all four requests outlined in a letter from the President dated July 31, 2025, the statement added.
Lower Costs for Diabetes and Cancer Medications
Under the terms of the agreement, U.S. Medicaid programs will gain access to certain Sanofi medications at prices comparable to those in other high-income countries. This is expected to reduce costs by an average of 61% for drugs used to treat diabetes, cardiovascular and neurological diseases, and cancer.
Sanofi will also offer patients access to lower-cost medications through platforms like TrumpRx.gov and other direct-to-patient channels, bypassing traditional pharmacies. “At Sanofi, we remain committed to collaborating with governments worldwide to ensure innovative medicines are recognized and accessible to patients,” said Sanofi CEO Paul Hudson in the statement.
Several pharmaceutical companies have already secured similar exemption agreements with the U.S. administration, including AstraZeneca (but not GSK), Novo Nordisk, and Merck. The agreements follow a September announcement by the President that the U.S. would impose a 100% tax on all imported patented drugs starting October 1, unless companies establish manufacturing facilities within the United States. This move underscores the administration’s focus on reshoring pharmaceutical production and lowering drug costs for American consumers.
